Frequency of Post-Treatment Recurrence After Short-Course Regimens for Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
- 1Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases” of the Ministry of Health of the Russian Federation, 4 Dostoevskogo St., Bldg. 2, Moscow 127473, Russia
- 2Chita State Medical Academy, Ministry of Health of the Russian Federation, 39A Gorkogo St., Chita 672000, Russia
Abstract
Background/Objectives: Short-course regimens (SCRs) are increasingly used to treat drug-resistant tuberculosis (DR-TB), but data on post-treatment recurrence remain limited. We aimed to estimate the frequency of post-treatment recurrence after SCRs and compare recurrence between SCRs and comparator regimens. Methods: We conducted a systematic review and meta-analysis of clinical studies reporting treatment duration, post-treatment follow-up, and recurrent tuberculosis episodes after SCRs for DR-TB. The primary single-arm analysis used a binomial-normal random-effects generalized linear mixed model (GLMM) based on r/A, retaining zero-event cohorts without a continuity correction. Comparative analyses used pooled risk ratios (RRs) and person-time-adjusted incidence rate ratios (IRRs). Results: Twenty-five studies contributed 26 SCR cohorts. In the primary analysis, 98 recurrent tuberculosis episodes occurred among 6954 patients; the pooled proportion was 1.24% (95% confidence interval [CI], 0.79–1.93%; 95% prediction interval, 0.24–6.21%). The pooled proportion was 1.20% (95% CI, 0.70–2.03%) for fully oral SCRs, 1.57% (0.85–2.85%) for pretomanid-containing SCRs, 1.55% (0.93–2.56%) for SCRs lasting ≤ 39 weeks, and 1.95% (1.20–3.15%) for SCRs lasting ≤ 36 weeks. In the overall comparative analysis, no statistically significant difference in post-treatment recurrence was observed between SCRs and comparator regimens: the pooled RR was 1.35 (95% CI, 0.34–5.40), and the person-time-adjusted IRR was 1.25 (95% CI, 0.50–3.15). In the randomized controlled trial (RCT) subset, the pooled RR indicated a higher recurrence risk with SCRs (RR, 2.72; 95% CI, 1.25–5.89), whereas the corresponding person-time-adjusted estimate did not show a statistically significant difference (IRR, 1.66; 95% CI, 0.81–3.43). This divergence indicates that comparative estimates are sensitive to how post-treatment follow-up duration is accounted for. Meta-regression identified no statistically significant associations between recurrence frequency and the examined cohort-level clinical characteristics. The certainty of evidence, assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, was low for the estimated recurrence frequency after fully oral SCRs, very low for the subgroup estimates, and low for the comparative estimates. Conclusions: These findings indicate a low frequency of post-treatment tuberculosis recurrence after SCRs and support the durability of treatment outcomes achieved with these regimens. However, substantial between-study heterogeneity and differences in post-treatment follow-up limit the interpretation of the pooled estimate as a uniform long-term recurrence risk. Further studies with standardized follow-up beginning at treatment completion are needed to provide more precise estimates of long-term outcomes after SCRs.
Related
- Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study
- Drivers of drug-resistant tuberculosis treatment initiation delay at three tertiary health facilities in Uganda: A mixed-methods study
- Pretreatment Attrition, Treatment Delay and Treatment Outcome in Drug-Resistant Tuberculosis: A Mixed-Methods Cohort Study in Public and Private Hospitals in Indonesia
- Early sputum bacterial load dynamics predict treatment response in multidrug-resistant/rifampicin-resistant tuberculosis: A multicenter prospective cohort study
- Household contact management of drug-resistant tuberculosis: a global cost-effectiveness modelling analysis of expanded preventive treatment by age
BibTeX
@article{ladyu2026frequency,
title = {{Frequency of Post-Treatment Recurrence After Short-Course Regimens for Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis}},
author = {Roman S. Ladyu and Anastasia I. Gaida and Viktor A. Mudrov and Platon I. Eliseev and Ruslan O. Khachetlov and Ksenia V. Rudakova and Valentina V. Tinkova and Anastasia G. Samoilova and Irina A. Vasilyeva},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218273},
url = {https://www.mdpi.com/2077-0383/15/21/8273},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Frequency of Post-Treatment Recurrence After Short-Course Regimens for Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
AU - Roman S. Ladyu
AU - Anastasia I. Gaida
AU - Viktor A. Mudrov
AU - Platon I. Eliseev
AU - Ruslan O. Khachetlov
AU - Ksenia V. Rudakova
AU - Valentina V. Tinkova
AU - Anastasia G. Samoilova
AU - Irina A. Vasilyeva
PY - 2026
DA - 2026/10/23
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218273
UR - https://www.mdpi.com/2077-0383/15/21/8273
AB - Background/Objectives: Short-course regimens (SCRs) are increasingly used to treat drug-resistant tuberculosis (DR-TB), but data on post-treatment recurrence remain limited. We aimed to estimate the frequency of post-treatment recurrence after SCRs and compare recurrence between SCRs and comparator regimens. Methods: We conducted a systematic review and meta-analysis of clinical studies reporting treatment duration, post-treatment follow-up, and recurrent tuberculosis episodes after SCRs for DR-TB. The primary single-arm analysis used a binomial-normal random-effects generalized linear mixed model (GLMM) based on r/A, retaining zero-event cohorts without a continuity correction. Comparative analyses used pooled risk ratios (RRs) and person-time-adjusted incidence rate ratios (IRRs). Results: Twenty-five studies contributed 26 SCR cohorts. In the primary analysis, 98 recurrent tuberculosis episodes occurred among 6954 patients; the pooled proportion was 1.24% (95% confidence interval [CI], 0.79–1.93%; 95% prediction interval, 0.24–6.21%). The pooled proportion was 1.20% (95% CI, 0.70–2.03%) for fully oral SCRs, 1.57% (0.85–2.85%) for pretomanid-containing SCRs, 1.55% (0.93–2.56%) for SCRs lasting ≤ 39 weeks, and 1.95% (1.20–3.15%) for SCRs lasting ≤ 36 weeks. In the overall comparative analysis, no statistically significant difference in post-treatment recurrence was observed between SCRs and comparator regimens: the pooled RR was 1.35 (95% CI, 0.34–5.40), and the person-time-adjusted IRR was 1.25 (95% CI, 0.50–3.15). In the randomized controlled trial (RCT) subset, the pooled RR indicated a higher recurrence risk with SCRs (RR, 2.72; 95% CI, 1.25–5.89), whereas the corresponding person-time-adjusted estimate did not show a statistically significant difference (IRR, 1.66; 95% CI, 0.81–3.43). This divergence indicates that comparative estimates are sensitive to how post-treatment follow-up duration is accounted for. Meta-regression identified no statistically significant associations between recurrence frequency and the examined cohort-level clinical characteristics. The certainty of evidence, assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, was low for the estimated recurrence frequency after fully oral SCRs, very low for the subgroup estimates, and low for the comparative estimates. Conclusions: These findings indicate a low frequency of post-treatment tuberculosis recurrence after SCRs and support the durability of treatment outcomes achieved with these regimens. However, substantial between-study heterogeneity and differences in post-treatment follow-up limit the interpretation of the pooled estimate as a uniform long-term recurrence risk. Further studies with standardized follow-up beginning at treatment completion are needed to provide more precise estimates of long-term outcomes after SCRs.
SN - 2077-0383
ER -